Jazz Pharmaceuticals(JAZZ) - 2025 Q1 - Earnings Call Presentation

Financial Performance & Guidance - Total revenues are projected to be between $4.15 billion and $4.40 billion, representing approximately 5% growth at the guidance midpoint[26] - The company anticipates Non-GAAP Adjusted Net Income (ANI) to be in the range of $250 million to $350 million[27] - Adjusted EPS is expected to be between $4.00 and $5.60[27] - The company had a strong operating cash flow of $430 million in 1Q25 and cash reserves of $2.6 billion at the end of 1Q25[27] - 1Q25 Non-GAAP ANI decreased 41% YoY to $105 million, and EPS decreased 36% YoY to $1.68, impacted by Xyrem antitrust litigation settlements[92] Product Performance - Xywav revenues grew 9% YoY in 1Q25, with Xywav remaining the 1 branded treatment for narcolepsy and the only therapy approved to treat Idiopathic Hypersomnia (IH)[24] - Epidiolex revenues increased 10% YoY in 1Q25 and is poised to reach blockbuster status in 2025[24, 40, 43] - Oncology revenues declined 11% YoY in 1Q25, impacted by SCLC competition for Zepzelca and COG protocol changes impacting Rylaze[24] - Total sleep therapeutic area revenue was $431 million in 1Q25[34] Pipeline Development - Zanidatamab is considered a near-term opportunity with a potential market opportunity exceeding $2 billion[5, 74] - Dordaviprone has a PDUFA action date of August 18, 2025, representing a near-term commercial opportunity[22, 87, 118]